✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Medicamen Biotech Ltd.

MEDICAMEQ

Market Cap
₹580 Cr.
P/E
68.91

Medicamen Biotech Ltd.

  • Medicamen Biotech
  • Kilitch Drugs(India)
  • Prevest Denpro
  • TJI Pharma - Small Cap
FAQs on Medicamen Biotech Ltd. Shareprice

Medicamen Biotech has given lower returns compared to its competitors.
Medicamen Biotech has grown at ~-13.08% over the last 3yrs while peers have grown at a median rate of 21.18%

Medicamen Biotech is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Medicamen Biotech is 69.54, while 3 year average PE is 61.57.
Also latest EV/EBITDA of Medicamen Biotech is 28.22 while 3yr average is 35.75.

View FAQ's On Business
Growth Table
  • Medicamen Biotech Ltd.
  • Kilitch Drugs(India)
  • Prevest Denpro
Balance Sheet
  • Medicamen Biotech Ltd.
  • Kilitch Drugs(India)
  • Prevest Denpro
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Medicamen Biotech Ltd.
  • Kilitch Drugs(India)
  • Prevest Denpro
Cash Flow
  • Medicamen Biotech Ltd.
  • Kilitch Drugs(India)
  • Prevest Denpro
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Medicamen Biotech Ltd.
  • Kilitch Drugs(India)
  • Prevest Denpro
Quarterly Results
  • Medicamen Biotech Ltd.
  • Kilitch Drugs(India)
  • Prevest Denpro
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Medicamen Biotech Ltd. Financials

Balance sheet of Medicamen Biotech is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Medicamen Biotech is increasing.
Latest debt of Medicamen Biotech is ₹13.75 Crs as of Sep-24.
This is greater than Mar-24 when it was ₹1.56 Crs.

No, profit is decreasing.
The profit of Medicamen Biotech is ₹6.67 Crs for TTM, ₹9.49 Crs for Mar 2024 and ₹14.73 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Medicamen Biotech latest dividend payout ratio is 13.39% and 3yr average dividend payout ratio is 10.06%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech